Prostate News Archive
29-Apr-2009
Prostate cancer vaccine extends survival in study (AP via Yahoo! News)
An experimental treatment added four months to the lives of men with advanced prostate cancer in a study that tested an entirely new approach to fighting the disease, doctors reported Tuesday. Dendreon Prostate Drug Extends Life 4 Months; Trading Halted (Bloomberg)
April 28 (Bloomberg) -- Dendreon Corp. ?s prostate cancer therapy Provenge, the first malignancy-fighting immune booster, extended men?s lives by four months in a study. Shares fell as much as 65 percent as investors waited for the data. Dendreon Prostate Drug Extends Life; Trading Halted (Update1) (Bloomberg)
April 28 (Bloomberg) -- Dendreon Corp. ?s prostate cancer therapy Provenge, the first malignancy-fighting immunotherapy, extended men?s lives by four months in a study. Shares fell as much as 65 percent as investors waited for the data, then more than doubled in after-hours trading. Avodart, Prostate Drug, Found to Reduce Cancer Risk (New York Times)
A drug from GlaxoSmithKline, Avodart, reduces the risk of prostate cancer, according to the results of a new large clinical study.
Back to Prostate News Archive
